Content deleted Content added
m Dating maintenance tags: {{Cn}} |
m →Research: replace removed reference with another suitable one |
||
Line 229:
Combinations of sofosbuvir with NS5A inhibitors, such as [[daclatasvir]], [[ledipasvir]] or [[Velpatasvir/sofosbuvir|velpatasvir]], have shown sustained virological response rates of up to 100% in people infected with HCV. Most studies indicate that the efficacy rate is between 94% and 97%; much higher than previous treatment options.<ref>{{cite journal | vauthors = Childs-Kean LM, Hand EO | title = Simeprevir and sofosbuvir for treatment of chronic hepatitis C infection | journal = Clinical Therapeutics | volume = 37 | issue = 2 | pages = 243–67 | date = February 2015 | pmid = 25601269 | doi = 10.1016/j.clinthera.2014.12.012 }}</ref><ref>{{cite journal | vauthors = Smith MA, Chan J, Mohammad RA | title = Ledipasvir-sofosbuvir: interferon-/ribavirin-free regimen for chronic hepatitis C virus infection | journal = The Annals of Pharmacotherapy | volume = 49 | issue = 3 | pages = 343–50 | date = March 2015 | pmid = 25515863 | doi = 10.1177/1060028014563952 | s2cid = 20944806 }}</ref><ref name=FDA2017Ep>{{Cite journal|url = https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm508915.htm|title = FDA approves Epclusa for treatment of chronic Hepatitis C virus infection|last = FDA|first = News Release|date = June 28, 2016|url-status = live|archive-url = https://web.archive.org/web/20170603100010/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm508915.htm|archive-date = June 3, 2017}}</ref> That treatments could be conducted at very low costs was demonstrated by Hill and coworkers who presented data on 1,160 patients who used generic versions of solfosbuvir, ledipasvir, plus daclatasvir from suppliers in India, Egypt, China and other countries and reported over 90% success at costs of about $50 per therapy.<ref name=merlot>{{cite magazine |url=http://www.spiegel.de/gesundheit/diagnose/hepatitis-c-koennte-fuer-50-dollar-therapiert-werden-a-1176133.html | first = Julia | last = Merlot | name-list-style = vanc |title=Hepatitis C könnte für 50 Dollar geheilt werden |magazine=[[Der Spiegel]] |language=de| date=November 2, 2017 |access-date=November 2, 2017}}</ref>
Sofosbuvir has also been tested against other viruses such as the [[Zika virus]]<ref>{{cite journal |last1=Sacramento |first1=Carolina Q. |last2=de Melo |first2=Gabrielle R. |last3=de Freitas |first3=Caroline S. |last4=Rocha |first4=Natasha |last5=Hoelz |first5=Lucas Villas Bôas |last6=Miranda |first6=Milene |last7=Fintelman-Rodrigues |first7=Natalia |last8=Marttorelli |first8=Andressa |last9=Ferreira |first9=André C. |last10=Barbosa-Lima |first10=Giselle |last11=Abrantes |first11=Juliana L. |last12=Vieira |first12=Yasmine Rangel |last13=Bastos |first13=Mônica M. |last14=de Mello Volotão |first14=Eduardo |last15=Nunes |first15=Estevão Portela |last16=Tschoeke |first16=Diogo A. |last17=Leomil |first17=Luciana |last18=Loiola |first18=Erick Correia |last19=Trindade |first19=Pablo |last20=Rehen |first20=Stevens K. |last21=Bozza |first21=Fernando A. |last22=Bozza |first22=Patrícia T. |last23=Boechat |first23=Nubia |last24=Thompson |first24=Fabiano L. |last25=de Filippis |first25=Ana M. B. |last26=Brüning |first26=Karin |last27=Souza |first27=Thiago Moreno L. |title=The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication |journal=Scientific Reports |date=18 January 2017 |volume=7 |issue=1 |page=40920 |doi=10.1038/srep40920|pmid=28098253 |pmc=5241873 |bibcode=2017NatSR...740920S |doi-access=free }}</ref> and [[severe acute respiratory syndrome coronavirus 2]] (SARS-CoV-2).<ref>{{cite journal|doi=10.1371/journal.pbio.3001845|title=SARS-CoV-2 infects human brain organoids causing cell death and loss of synapses that can be rescued by treatment with Sofosbuvir |year=2022 |last1=
== See also ==
| |||